Oral oestrogen replacement therapy versus placebo for hot flushes

MacLennan, Alastair H.; Lester, Sue; Moore, Vivienne

doi:10.1002/14651858.cd002978

Cited by 84 publications

(56 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Placebo treatment as such has been suggested to induce β-endorphin release, based on the fact that placebo-induced pain relief can be blocked by naloxone 35,36 . A number of studies show that placebo effects cause nearby 50% reduction of flushes 37 but most of these studies did not have an observation time of more than 3 months. However, other studies show no or very little effect on vasomotor symptoms of placebo during 12 weeks of treatment or longer 38 .…”

Section: Discussionmentioning

confidence: 99%

Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study

et al. 2005

View full text Add to dashboard Cite

Objective: To evaluate the effect of applied relaxation and electro-acupuncture on vasomotor symptoms in women treated for breast cancer.Methods: Thirty-eight postmenopausal women with breast cancer and vasomotor symptoms were randomized to treatment with electro-acupuncture (n = 19) or applied relaxation (n = 19) during 12 weeks. The number of hot flushes was registered daily in a logbook before and during treatment and after 3 and 6 months of follow-up.Results: Thirty-one women completed 12 weeks of treatment and 6 months of follow-up. After 12 weeks of applied relaxation, the number of flushes/24 h had decreased from 9.2 (95% confidence interval (CI) 6.6-11.9) at baseline to 4.5 (95% CI 3.2-5.8) and to 3.9 (95% CI 1.8-6.0) at 6 months follow-up (n = 14). The flushes/24 h were reduced from 8.4 (95% CI 6.6-10.2) to 4.1 (95% CI 3.0-5.2) after 12 weeks of treatment with electro-acupuncture and to 3.5 (95% CI 1.7-5.3) after 6 months follow-up (n = 17). In both groups, the mean Kupperman Index score was significantly reduced after treatment and remained unchanged 6 months after end of treatment. Conclusion:We suggest that applied relaxation and electro-acupuncture should be further evaluated as possible treatments for vasomotor symptoms in postmenopausal women with breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In general, reviews of alternative and complimentary nonhormonal therapies indicate that large randomized placebo controlled trials are lacking and these therapies are not as effective as oestrogen at controlling vasomotor symptoms. The fact that there is a 50% improvement in symptoms with placebo highlights the requirement for large robust blinded randomised trials [77].…”

Section: Non-hormonal Therapiesmentioning

confidence: 99%

Iatrogenic Menopause After Treatment for Cervical Cancer

et al. 2016

View full text Add to dashboard Cite

“…Todos os tipos de TH (tipo de estrogênio, doses, via de administração com ou sem adição de progestágeno) são eficazes. Em uma revisão sistemática publicada pelo Instituto Cochrane, envolvendo 21 estudos randomizados e duplo-cegos sobre o efeito da TH comparada a placebo, totalizando 2.511 pacientes, verificou-se 77% de melhora dos fogachos nas usuárias de TH comparada a uma melhora de 30% no grupo placebo (15).…”

Section: Sintomas Vasomotoresunclassified

Terapia hormonal da menopausa

Pardini

2007

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOEmbora a reposição estrogênica esteja disponível há mais de 6 décadas, as mulheres e mesmo os profissionais da saúde estão confusos pelas opiniões divergentes em relação aos riscos e benefícios da terapia hormonal na menopausa (THM), estrogênica (TE) ou estro-progestagênica (TEP). A principal indicação para terapêutica hormonal na menopausa é o alívio dos sintomas menopausais, tais como sintomas vasomotores, alterações gênito-urinárias e a prevenção de osteoporose nas pacientes de risco. Em outras áreas de pesquisa, principalmente ao que se refere aos efeitos nos sistemas cardiovasculares e nervoso central, os resultados atuais na literatura são conflitivos. O tratamento por mais de 5 anos não adiciona risco significativo para câncer de mama, mas diminui significativamente o risco de fratura osteoporótica. Algumas mulheres podem ser susceptíveis a risco tromboembólico precoce, mas quando a TH for adequada após avaliação individualizada, os benefícios superam os riscos e o tratamento deve ser recomendado. Estudos futuros são necessários para identificar novas indicações para TH e diminuir ou abolir seus riscos. A pesquisa clínica continua na identificação de fatores genéticos que possam influenciar a resposta individual à TH, diferentes formulações estrogênicas, diferentes vias de administração e liberação, além das opções de dose. Nas mulheres que apresentam os sintomas da síndrome climatérica de forma severa durante a peri e pós-menopausa já existem evidências conclusivas oriundas de vários estudos randomizados controlados de que a TH é a única terapia com resultados satisfatórios. Os médicos devem sempre fazer suas decisões terapêuticas com base nos riscos e benefícios individuais de cada paciente, tendo a responsabilidade e o dever de promover as condições para a mulher atravessar a transição menopáusica com qualidade de vida. Although estrogen has been clinically available for more than 6 decades, women have been confused by different opinions regarding the risks and benefits of menopausal hormone therapy (HT), estrogen therapy (ET), and estrogen-progestin therapy (EPT). The main indication for HT use in postmenopausal women remains the relief of vasomotor symptoms and vulvovaginal atrophy, and is effective in the prevention of osteoporosis. In other areas of research, notably in cardiovascular and central nervous system effects, the recent literature has produced conflicting results. Treatment for up to 5 years does not add significantly to lifetime risk of breast cancer, but significantly decreases bone loss and risk of osteoporotic fractures. Some women may be susceptible to early thrombotic risk, but when appropriate HT is given after individual clinical evaluation, the benefits will far outweigh any potential risks and the treatment should be recommended. Clinical research continues into genetic factors influencing the response to ET/HT, different estrogen formulations, different modes of delivery and lower-dose options. Patients and clinicians should make treatment decisions on the basis of an in...

show abstract

Oral oestrogen replacement therapy versus placebo for hot flushes

Cited by 84 publications

References 78 publications

Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study

Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study

Iatrogenic Menopause After Treatment for Cervical Cancer

Terapia hormonal da menopausa

Contact Info

Product

Resources

About